IMMUNOVANT INC.
IMMUNOVANT INC.
- USD (-)
- 15 min Ritardato - Azioni NASDAQ
Apertura: -
Variazione: -
Volumi: -
Minimo: -
Massimi: -
Distanza Mas/Min: -
Tipologia: Azioni
Ticker: IMVT
ISIN:

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

  • 135

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

To participate in the conference call, please register in advance here. To access the live and archived webcast, please visit Immunovant’s website at https://www.immunovant.com/investors/news-events. The archived webcast will be available for a limited time on the Company’s website.

About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com

Contact:
Chau Cheng, PhD, MBA
Vice President, Investor Relations
Immunovant, Inc.
[email protected]

ti?nf=ODkyODM5MSM1ODMwNjk5IzIxMjU4NDQ=
Immunovant-Inc-.png
GlobeNewsWire
GlobeNewsWire

GlobeNewswire è una delle più grandi reti di distribuzione di newswire al mondo, specializzata nella distribuzione di comunicati stampa aziendali, informazioni finanziarie e contenuti multimediali a media, investitori e lettori di tutto il mondo.